MicroRNA-5572 Is a Novel MicroRNA-Regulating


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
24 Jun 2020
Historique:
received: 28 05 2020
revised: 19 06 2020
accepted: 22 06 2020
entrez: 1 7 2020
pubmed: 1 7 2020
medline: 23 3 2021
Statut: epublish

Résumé

Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease caused by the loss of motor neurons. Although the pathogenesis of sporadic ALS (sALS) remains unclear, it has recently been suggested that disorders of microRNA (miRNA) may be involved in neurodegenerative conditions. The purpose of this study was to investigate miRNA levels in sALS and the target genes of miRNA. Microarray and real-time RT-PCR analyses revealed significantly-decreased levels of miR-139-5p and significantly increased levels of miR-5572 in the spinal cords of sALS patients compared with those in controls. We then focused on miR-5572, which has not been reported in ALS, and determined its target gene. By using TargetScan, we predicted

Identifiants

pubmed: 32599739
pii: ijms21124482
doi: 10.3390/ijms21124482
pmc: PMC7350020
pii:
doi:

Substances chimiques

Biomarkers 0
Cation Transport Proteins 0
MicroRNAs 0
SLC30A3 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 15K21278
Organisme : Japan Society for the Promotion of Science
ID : 17K18001
Organisme : Japan Society for the Promotion of Science
ID : JP19H05767A02
Organisme : the Collaborative Research Project of Brain Research Institute, Niigata University
ID : 2019-23
Organisme : Grant-in-Aid of The Nakabayashi Trust For ALS Research
ID : 28-16

Références

Tumour Biol. 2015 Sep;36(9):6741-9
pubmed: 25833697
Expert Rev Neurother. 2016 Dec;16(12):1397-1405
pubmed: 27362330
Biochem Biophys Res Commun. 2016 Oct 28;479(4):853-859
pubmed: 27678294
J Neurosci Res. 2015 Feb;93(2):370-9
pubmed: 25284286
Acta Neuropathol Commun. 2014 Dec 14;2:173
pubmed: 25497327
PLoS One. 2014 Feb 20;9(2):e89065
pubmed: 24586506
Cell Mol Life Sci. 2016 Feb;73(4):811-27
pubmed: 26608596
Nat Rev Genet. 2011 Feb;12(2):99-110
pubmed: 21245828
J Neurol Sci. 2016 Sep 15;368:19-24
pubmed: 27538595
Nature. 2016 Nov 10;539(7628):197-206
pubmed: 27830784
Cancer Sci. 2016 Sep;107(9):1233-42
pubmed: 27355528
J Neurol Sci. 2011 Apr 15;303(1-2):95-9
pubmed: 21292280
Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):98-103
pubmed: 28872911
PLoS One. 2012;7(3):e33211
pubmed: 22427991
Neurogenetics. 2014 Oct;15(4):243-53
pubmed: 25130371
Muscle Nerve. 2018 Aug;58(2):261-269
pubmed: 29466830
Neurobiol Dis. 2013 Jan;49:107-17
pubmed: 22975021
Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):973-85
pubmed: 16973338
Mol Neurobiol. 2015;51(3):1249-62
pubmed: 24973986
Int J Biol Sci. 2015 Feb 05;11(3):345-52
pubmed: 25678853
Acta Neuropathol. 2016 Oct;132(4):487-502
pubmed: 27282474

Auteurs

Hisaka Kurita (H)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

Saori Yabe (S)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

Tomoyuki Ueda (T)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

Masatoshi Inden (M)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

Akiyoshi Kakita (A)

Department of Pathology, Brain Research Institute, Niigata University, 1 Asahimachi, Chuo-ku, Niigata 951-8585, Japan.

Isao Hozumi (I)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH